drugset / Trial / NCT01296659
Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma
Phase 1
Withdrawn
The University of Texas Health Science Center at San Antonio
Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Ridaforolimus has been tested in almost 2 dozen studies; however, it has not previously been tested in combination with the standard of care chemotherapy for sarcoma as this study will. We will be looking to see if Ridaforolimus given with SOC chemo (AIM or TG) is well tolerated and to determine a Phase 2 dose.
Timeline
- Start
- 2011-02
- Primary completion
- 2011-08
- Completion
- 2011-08
Outcome
Outcome not reported
Stopped: “Principal Investigator left institution.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ridaforolimus | Small molecule | — | Oral |